SCHEMBL6511094

SCHEMBL6511094

Cc1c2c(=O)n(CCC3CO3)c3ccc(Cl)cc3c2nn1C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 3/20 0.41
CNR2 P34972 7/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 1/20 0.35
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32
MAPK8 P45983 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6514165 0.91 CHEK1 (0.39) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6522000 0.87 CHEK1 (0.41) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6511866 0.86 CHEK1 (0.38) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6516690 0.86 CHEK1 (0.42) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6515376 0.83 MAPT (0.41) CHEK1CNR2MAPTLMNAKMT2A
SCHEMBL6522817 0.81 CHEK1 (0.39) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6510992 0.81 ALOX5AP (0.36) CHEK1CNR2ALDH1A1MAPTLMNA
SCHEMBL6525478 0.81 CHEK1 (0.36) CHEK1CNR2
SCHEMBL6515427 0.80 ALDH1A1 (0.41) CHEK1CNR2KDM4EALDH1A1MAPT
SCHEMBL6511097 0.80 IDH1 (0.33) CHEK1CNR2KMT2ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885CNR2 3139/4885KDM4E 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.